Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Petros Pharmaceuticals, Inc.PTPI · Entity 8730 | See Remarks | June 05, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Petros Pharmaceuticals, Inc.
Report date June 05, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 894,986 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 375,000 · Balance 894,986 F1: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 5, 2026 21:25 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | GrantCommon Stock | 375,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-071048 · tm2617013-3_4seq1.xml · nonDerivative · entry 1 Boctor Fady · CIK 0001833394 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 894,986 F1 · shares: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. F1 · price: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:30 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | GrantCommon Stock | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-001417 · tm261718-2_4seq1.xml · nonDerivative · entry 1 Boctor Fady · CIK 0001833394 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 519,986 F1 · shares: Represents Restricted Stock Units ("RSUs"). 50% of the RSUs vested on the date of grant and the remaining 50% will vest on the six month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. Each RSU represents the right to receive one share of common stock, par value $0.0001 per share (the "Common Stock"), of the Issuer. F1 · price: Represents Restricted Stock Units ("RSUs"). 50% of the RSUs vested on the date of grant and the remaining 50% will vest on the six month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. Each RSU represents the right to receive one share of common stock, par value $0.0001 per share (the "Common Stock"), of the Issuer. F2 · balance_after: Amounts adjusted for the Issuer's 1-for-25 reverse stock split of the Issuer's Common Stock, effective as of 4:05 p.m. (New York time) on April 30, 2025. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:31 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | GrantCommon Stock | 450,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-016200 · tm257316-2_4seq1.xml · nonDerivative · entry 1 Boctor Fady · CIK 0001833394 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 499,645 F1 · price: Represents a grant of restricted shares of common stock, par value $0.0001 per share, of the Issuer granted under the Petros Pharmaceuticals, Inc. Amended and Restated 2020 Omnibus Incentive Compensation Plan, as amended. 50% of the shares vest on the first anniversary of the date of grant and the remaining shares vest on the second anniversary on the date of grant, provided that the Reporting Person continues to provide service to the Issuer on the applicable vesting date. Read SEC document |
| December 21, 2023 Filed Dec 26, 2023 22:07 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | GrantStock Option (Right to Buy) · Derivative | 54,533 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001104659-23-129254 · tm2333705-6_4seq1.xml · derivative · entry 2 Boctor Fady · CIK 0001833394 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,533 Underlying: Common Stock · 54,533 shares Expires 2033-12-21 F1 · derivative.exercise_date: The stock options vested 50% upon the date of grant, and the remainder vests upon the achievement of certain performance goals, provided that the Reporting Person has continued to provide services to the Company through the vesting date. Read SEC document |
| December 21, 2023 Filed Dec 26, 2023 22:07 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | GrantCommon Stock | 49,645 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-129254 · tm2333705-6_4seq1.xml · nonDerivative · entry 1 Boctor Fady · CIK 0001833394 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,645 Read SEC document |
| February 19, 2021 Filed Mar 2, 2021 00:16 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | GrantStock Options (right to buy) · Derivative | 215,669 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001567619-21-005214 · doc1.xml · derivative · entry 1 Boctor Fady · CIK 0001833394 · Pres. & Chief Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,669 Underlying: Common Stock · 215,669 shares Expires 2031-02-19 F1 · derivative.exercise_date: The options vested 50% as of February 19, 2021, the date of grant, and the remainder vest in equal installments on the first and second annual anniversaries thereof. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.